UnitedHealth Favors Harvoni For Hepatitis C; Medicaid Programs Weighing Options
This article was originally published in The Pink Sheet Daily
UnitedHealth joins CVS, Anthem and Aetna in offering preferred coverage for Gilead’s hepatitis C drugs Harvoni and Sovaldi in return for discounted pricing, while designating AbbVie’s Viekira Pak as non-preferred.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.